The rheumatoid arthritis drug methotrexate, has been show to be a cheaper and effective alternative for blood cancer sufferers. Researchers have found that methotrexate can have the same effect on patients with blood disorders that the drug Ruxolitinib has. Because methotrexate is a World Health Organization ‘Essential Medicine,’ this also means that this well understood drug could be used throughout the developing world.
The potential to repurpose methotrexate could provide thousands of patients with a much needed treatment option and also generate substantial savings for health care systems given it is roughly $11,000 less a year to obtain than Ruxolitinib.
Original research article can be found at PLOS